Alnylam Pharmaceuticals Stock Forecast & Price Target
Alnylam Pharmaceuticals Price Target 2026
The Quantum Forecast sees a price target of $138.65 (−9.6%) for Alnylam Pharmaceuticals in about one month (by Dec 10, 2026).
Quantum Forecast price targets by time frame, calculated from the current price of $153.35. Click to see the forecast in the chart.
Alnylam Pharmaceuticals Forecast for Today and Tomorrow
In the short term, the Quantum Forecast sees Alnylam Pharmaceuticals at $153.02 (−0.22%) today around 10:30 AM ET and at $153.76 (+0.27%) tomorrow around 2:15 AM ET. It is based on prices from the current trading day and the past week. Short-term forecast in the chart
Alnylam Pharmaceuticals Stock 2026: Price Performance
Alnylam Pharmaceuticals stock has lost 61.4% since the start of 2026 and currently trades at $153.35 (as of Nov 11, 2026). Over the same period the Nasdaq 100 is up 11.5%, putting the stock 73.0 percentage points behind the index. Over the past 52 weeks the price ranged between $150.04 and $481.44; it is currently 68.1% below its high of Dec 3, 2025.
Alnylam Pharmaceuticals Forecast 2027
Over a horizon of roughly 10 months (until about Sep 2027), the Quantum Forecast sees a price target of $118.35 for Alnylam Pharmaceuticals – −22.8% from today. The range band runs from $11.84 – $224.87: the further ahead the forecast looks, the greater the uncertainty. See the long-term forecast in the chart
Community Forecast for Alnylam Pharmaceuticals
There are no user forecasts for Alnylam Pharmaceuticals yet – be the first to make one.
Make your own forecastAbout Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biotech company headquartered in Cambridge, Massachusetts, founded in 2002. It pioneered RNA interference (RNAi) therapeutics, which use small interfering RNA molecules to silence genes responsible for disease. Alnylam brought the first RNAi drug, Onpattro, to market in 2018, followed by Givlaari, Oxlumo, Amvuttra and Leqvio, the latter licensed to Novartis for lowering LDL cholesterol.
The most important growth driver is Amvuttra, which was approved for the treatment of cardiomyopathy caused by transthyretin amyloidosis (ATTR-CM), a heart condition affecting a much larger patient population than earlier indications. Competition in ATTR comes from Pfizer, BridgeBio and others. Alnylam is also developing RNAi drugs for more common conditions such as hypertension and Alzheimer's disease, partly with partners such as Roche and Regeneron. Clinical trial results, regulatory approvals and pricing are central for the stock. Alnylam trades on the Nasdaq under the ticker ALNY and is a member of the Nasdaq-100.
The current price of Alnylam Pharmaceuticals stock is $153.35 (+0.66% vs. the previous close). In today's trading the high was $153.35 and the low $151.41.
How the Quantum Forecast works
Research from quantum physics. The models are the result of several years of research at the Max Planck Institute of Quantum Optics and LMU Munich and were transferred to the stock market.
Spectra and correlations. Frequency spectra are calculated from current prices, and the relationships between price swings and volatility are analyzed. This produces the forecast and the risk assessment.
Detecting herd behavior. Models of phase transitions from statistical physics describe when investors collectively fall into panic or euphoria – an early sign of possible crash situations.
Swarm intelligence. User forecasts are checked once their time frame has expired and feed into the model, weighted by their hit rate.
The range band shows the typical fluctuation around the forecast. More on quantum physics & swarm intelligence
Frequently Asked Questions about Alnylam Pharmaceuticals Stock
What is the Alnylam Pharmaceuticals stock forecast?
The Quantum Forecast expects Alnylam Pharmaceuticals to reach $138.65 in about one month (by Dec 10, 2026), a change of −9.6% from the current price of $153.35. Over roughly 10 months (by Sep 2027) the price target is $118.35 (−22.8%).
What is the Alnylam Pharmaceuticals stock price target?
Quantum Forecast price targets by time frame: 1 month $138.65 (−9.6%), 2 months $176.05 (+14.8%), 6 months $135.62 (−11.6%), 10 months $118.35 (−22.8%). The range band shows the typical fluctuation around these targets.
Will Alnylam Pharmaceuticals stock go up or down?
In the short term the Quantum Forecast points down (−9.6% over one month). No forecast is certain – it is based on historical prices and statistical analysis.
How is the Quantum Forecast computed?
Trends, frequency spectra and correlations are calculated from the price history using methods from quantum physics; user opinions are added as well (swarm intelligence). The range band reflects the volatility of the security and widens with the time horizon.
Can I make my own forecast for Alnylam Pharmaceuticals?
Yes – in the Forecast League you pick long or short and a price target for 1 day up to 6 months. Forecasts are scored automatically when they expire; correct calls earn points and a spot on the leaderboard.